Home › Major Depressive Disorder › Georgia
Pag-aaral pangklinika para sa Major Depressive Disorder sa Georgia
31 pag-aaral para sa Major Depressive Disorder ang naghahanap ng mga kalahok sa mga site sa Georgia.
Mga Lungsod sa Georgia
Opisyal na teksto ng pag-aaral (English)
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Psych Atlanta, Marietta
Nagre-recruitPhase 3
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Atlanta
- Seaport Investigator Site, Decatur
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07065240Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
- Emory Healthcare, Atlanta
Nagre-recruit
Edad 22 hanggang 85 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07594483A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- CenExel - Atlanta Center for Medical Research, Atlanta
- CenExel - iResearch Atlanta, Decatur
- CenExel - iResearch Savannah, Savannah
Nagre-recruitPhase 3
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07592689A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- CenExel iResearch, LLC, Decatur
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07412756Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Agile Clinical Research Trials, LLC, Atlanta
Nagre-recruitPhase 3
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06559306A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Peachford Hospital-Atlanta Behavioral Research, Atlanta
Nagre-recruitPhase 3
Edad 12 hanggang 17 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07227454A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- CenExel iResearch, LLC, Decatur
- AGILE Clinical Research Trials, LLC, Sandy Springs
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- The Emory Clinic, Atlanta
- CenExeli Research LLC, Decatur
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05850689A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Agile Clinical Research Trials, LLC, Atlanta
- Accelerated Clinical Research Group LLC, Snellville
Nagre-recruitPhase 3
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07573176Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Atlanta
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT06966401A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Clinical Research Site, Norcross
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT07621237Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Cenexel Atlanta (ACMR), Atlanta
- Cenexel iResearch Atlanta, Decatur
Nagre-recruitPhase 2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT07226661Study of ALTO-300 in MDD
- Site 238, Fayetteville
- Site 293, Stone Mountain
Nagre-recruitPhase 2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT05922878Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Emory University Hospital, Atlanta
Nagre-recruit
Edad 22 hanggang 70 · Lahat ng kasarian · Na-update Okt 16, 2026 · NCT06423430A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Decatur
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 14, 2026 · NCT07610473Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Atlanta
- Clinical Research Site, Norcross
- Clinical Research Site, Snellville
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT07484217A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Atlanta
- Draig Clinical Site, Decatur
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 8, 2026 · NCT07300969JAK Signaling in Depression
- Emory University, Atlanta
Nagre-recruitPhase 2
Edad 25 hanggang 55 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07003997Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Snellville
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Augusta
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT07105111Leucine in Midlife Depression
- Emory University Hospital, Atlanta
Nagre-recruitPhase 2
Edad 35 hanggang 65 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06580145NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Atlanta
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06911112Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- CenExel iRS (iResearch Savannah), Savannah
Nagre-recruitPhase 2
Edad 18 hanggang 64 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Denali Health Atlanta, LLC, Stone Mountain
Nagre-recruitPhase 2
Edad 18 hanggang 64 · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT07115329A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Trialmed /ID# 277601, Atlanta
- Evergreen Clinical Trials - Norcross /ID# 279421, Norcross
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT07276997Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
- Emory University, Atlanta
Nagre-recruitMaagang Phase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update May 26, 2026 · NCT05327699REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
- Savannah VA Clinic, Savannah
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 29, 2026 · NCT07280065Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Georgia, Athens
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 40 · Lahat ng kasarian · Na-update Mar 10, 2026 · NCT06740383Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #112, Decatur
- Autobahn Site #142, Peachtree Corners
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT06633016A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Atlanta
Nagre-recruitPhase 4
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Ene 23, 2025 · NCT06223880Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.